Biogen halves price of controversial Alzheimer's drug | The Hill: Healthcare Policy

Biogen on Monday cut in half the price of its Alzheimer's drug Aduhlem in an effort to boost lackluster sales that stemmed in part from controversy over its price. The company said Aduhelm will cost $28,200 per year for an average weight...